Specificity of tissue transglutaminase explains cereal toxicity in celiac disease
- PMID: 11877487
- PMCID: PMC2193762
- DOI: 10.1084/jem.20012028
Specificity of tissue transglutaminase explains cereal toxicity in celiac disease
Abstract
Celiac disease is caused by a selective lack of T cell tolerance for gluten. It is known that the enzyme tissue transglutaminase (tTG) is involved in the generation of T cell stimulatory gluten peptides through deamidation of glutamine, the most abundant amino acid in gluten. Only particular glutamine residues, however, are modified by tTG. Here we provide evidence that the spacing between glutamine and proline, the second most abundant amino acid in gluten, plays an essential role in the specificity of deamidation. On the basis of this, algorithms were designed and used to successfully predict novel T cell stimulatory peptides in gluten. Strikingly, these algorithms identified many similar peptides in the gluten-like hordeins from barley and secalins from rye but not in the avenins from oats. The avenins contain significantly lower percentages of proline residues, which offers a likely explanation for the lack of toxicity of oats. Thus, the unique amino acid composition of gluten and related proteins in barley and rye favors the generation of toxic T cell stimulatory gluten peptides by tTG. This provides a rationale for the observation that celiac disease patients are intolerant to these cereal proteins but not to other common food proteins.
Figures



Similar articles
-
Characterization of cereal toxicity for celiac disease patients based on protein homology in grains.Gastroenterology. 2003 Oct;125(4):1105-13. doi: 10.1016/s0016-5085(03)01204-6. Gastroenterology. 2003. PMID: 14517794
-
A quantitative analysis of transglutaminase 2-mediated deamidation of gluten peptides: implications for the T-cell response in celiac disease.J Proteome Res. 2009 Apr;8(4):1748-55. doi: 10.1021/pr800960n. J Proteome Res. 2009. PMID: 19239248
-
The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase.J Exp Med. 2000 Feb 21;191(4):603-12. doi: 10.1084/jem.191.4.603. J Exp Med. 2000. PMID: 10684852 Free PMC article.
-
Pathomechanisms in celiac disease.Int Arch Allergy Immunol. 2003 Oct;132(2):98-108. doi: 10.1159/000073710. Int Arch Allergy Immunol. 2003. PMID: 14600421 Review.
-
Coeliac disease--a meeting point for genetics, immunology, and protein chemistry.Lancet. 2003 Apr 12;361(9365):1290-2. doi: 10.1016/s0140-6736(03)12989-3. Lancet. 2003. PMID: 12699968 Review.
Cited by
-
Shared and unique common genetic determinants between pediatric and adult celiac disease.BMC Med Genomics. 2016 Jul 22;9(1):44. doi: 10.1186/s12920-016-0211-8. BMC Med Genomics. 2016. PMID: 27449795 Free PMC article.
-
Oral enzyme therapy for celiac sprue.Methods Enzymol. 2012;502:241-71. doi: 10.1016/B978-0-12-416039-2.00013-6. Methods Enzymol. 2012. PMID: 22208988 Free PMC article.
-
No allelic variation in genes with high gliadin homology in patients with celiac disease and type 1 diabetes.Immunogenetics. 2004 Aug;56(5):375-8. doi: 10.1007/s00251-004-0696-8. Epub 2004 Aug 7. Immunogenetics. 2004. PMID: 15309343
-
Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue.J Proteome Res. 2005 Sep-Oct;4(5):1732-41. doi: 10.1021/pr050173t. J Proteome Res. 2005. PMID: 16212427 Free PMC article.
-
The molecular basis for oat intolerance in patients with celiac disease.PLoS Med. 2004 Oct;1(1):e1. doi: 10.1371/journal.pmed.0010001. Epub 2004 Oct 19. PLoS Med. 2004. PMID: 15526039 Free PMC article.
References
-
- Marsh, M.N. 1992. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (‘celiac sprue’). Gastroenterology. 102:330–354. - PubMed
-
- Dieterich, W., T. Ehnis, M. Bauer, P. Donner, U. Volta, E.O. Riecken, and D. Schuppan. 1997. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat. Med. 3:797–801. - PubMed
-
- Molberg, O., S.N. McAdam, R. Korner, H. Quarsten, C. Kristiansen, L. Madsen, L. Fugger, H. Scott, O. Noren, P. Roepstorff, K.E. Lundin, H. Sjostrom, and L.M. Sollid. 1998. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4:713–717. - PubMed
-
- van de Wal, Y., Y. Kooy, P. van Veelen, S. Pena, L. Mearin, G. Papadopoulos, and F. Koning. 1998. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J. Immunol. 161:1585–1588. - PubMed
-
- Spurkland, A., G. Ingvarsson, E.S. Falk, I. Knutsen, L.M. Sollid, and E. Thorsby. 1997. Dermatitis herpetiformis and celiac disease are both primarily associated with the HLA-DQ (α1*0501, β1*02) or the HLA-DQ (α1*03, β1*0302) heterodimers. Tiss. Anttigens. 49:29–34. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical